Relapsed ovarian cancer: Paboli pearl monoantigen anti-combined beval bead monoantigen and cyclophosphamide treatment is safe and effective

Zsiros of the Roswell Park Comprehensive Cancer Center in the United States, among others, reported good resistance to Pablic beading and oral cyclophosphamide in this Phase II non-randomized clinical trial, with a clinical benefit rate of 95.0% and a continuous remission rate of 25.0% in patients with relapsed ovarian cancer.
this joint program or become a future treatment strategy for relapsed ovarian cancer.
(JAMA Oncol. doi: 10.1001/jamaoncol.2020.5945) has limited clinical benefits from treatment options for relapsed ovarian cancer and poor quality of life in patients, indicating that the need for effective and toadable therapies has not been met.
In platinum-sensitive recurring, platinum-resistant or incurable epithelial ovarian, fallopian or primary peritina cancers, the study was designed to assess the efficacy and safety of Pablo's bead monoantigen and regular oral cyclophosphamide.
September 6, 2016 to June 27, 2018, the Open One Arm II. Phase II. Queue Study recruited patients at an agency in the United States and analyzed data from September 6, 2016 to February 20, 2020.
eligible patients are relapsed ovarian cancer, there is a measurable disease based on the immune-related solid tumor response assessment criteria (irRECIST), and the ECOG PS score is 0 to 1.
During the treatment cycle, the patient receives 200 mg of Pabli pearl monoantigen and 15 mg/kg of beva bead monoanti (every 3 weeks) daily, as well as 50 mg of cyclophosphamide oral until the disease progresses, an unacceptable toxicity occurs, or consent is withdrawn.
results are objective mitigation rates (ORRs) and progress-free lifetimes (PFS).
of the 40 patients, 30 (75.0%) were platinum-resistant ovarian cancer and 10 (25.0%) were platinum-sensitive ovarian cancer with an average age of 62.2 years ±9.4 years).
according to the irreCIST standard, there were 3 cases (7.5%) of complete remission of treatment, 16 cases (40.0%) partial remission, 19 cases (47.5%) of stable condition, ORR of 47.5%, 38 cases (95.0%) of clinical benefits, 10 cases (25.0%) of continuous remission.
PFS is 10.0 months (90% CI6.5 to 17.4 months).
the most common level 3 to 4 adverse events associated with treatment were hypertension (6 cases, 15.0%) and decreased lymphocytes (3 cases, 7.5%).
most commonly reported adverse events include fatigue (18 cases, 45.0%), diarrhea (13 cases, 32.5%) and hypertension (11 cases, 27.5%).
Her Royal Highness the Queen: Zhang Shi's former public number copyright notice: All text, images and audio and video materials on this website that indicate "Source: Mets Medicine" or "Source: MedSci Original" are owned by Mets Medicine and are not authorized to be reproduced by any media, website or individual, and are authorized to be reproduced with the words "Source: Mets Medicine".
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
at the same time reproduced content does not represent the position of this site.
leave a message here